Patent ID: 8618096

Claim:
A prodrug having the formula wherein, X is â€”Oâ€”; Z 1 together with L 1 is a drug; L 1 is â€”N(R 6 )â€”, â€”Oâ€” or â€”OC(O)â€”; L 2 is a bond, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, â€”C(O)N(R 7 )â€” or â€”N(R 7 )â€”C(O)â€”; L 3 is â€”OC(O)â€” or a bond, with the proviso that if L 1 is â€”OC(O)â€”, then L 3 is a bond; R 1a and R 1b are independently hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 2 is hydrogen or an electron withdrawing moiety; R 3 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R 4 and R 5 are joined together to form a ring moiety having at least 6 atoms, said ring moiety selected from substituted or unsubstituted cycloalkyl or substituted or unsubstituted heterocycloalkyl; R 6 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and R 7 is hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; wherein said drug is an anti-malarial drug or anti-cancer drug capable of treating malaria or cancer that is associated with a cell or organism having increased Fe II levels compared to Fe II levels in mammalian plasma.